Anti-Certolizumab Polyclonal Antibody (AF879054)

Name: Anti-Certolizumab Polyclonal Antibody
Brand: abinScience
SKU: AF879054
Price: 168 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

50ug
100ug
1mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue

AF879054

Description

Anti-Certolizumab Polyclonal Antibody (AF879054) is a rabbit polyclonal antibody detecting Certolizumab in ELISA.

Highlights

●Affinity Purified — Minimal background and high purity for reliable results.

Reactivité des espèces

General

Applications

ELISA

Espèce hôte

Rabbit

Clonalité

Polyclonal

Isotype

IgG

Immunogène

Certolizumab

Cible

Certolizumab

Spécificité

The product is specific for Certolizumab. This antibody serves as an excellent positive control for Certolizumab immunogenicity (ADA) assays.

Niveau d'endotoxines

Please contact with the lab for this information.

Pureté

>90% as determined by SDS-PAGE.

Purification

Purified by antigen affinity column.

Numéro d'accès

CAS: 428863-50-7

Forme

Liquid

Tampon de stockage

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.

Informations d'utilisation du produit

Application	Dilution
ELISA	1:5000-1:20000
IHC	1:50-1:500
WB	1:500-1:2000

Stabilité et stockage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Contexte

Certolizumab is a Fab fragment of a monoclonal antibody to human tumor necrosis factor alpha (TNFα) which has potent antiinflammatory activity and is used in the therapy of severe rheumatoid arthritis and inflammatory bowel disease. Antibodysystem Anti-Certolizumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Certolizumab.
• Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial., PMID:37423647
• Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis., PMID:32207094
• Certolizumab Pegol in Plaque Psoriasis: Considerations for Pregnancy., PMID:33769772
• Certolizumab treatment of localized pyoderma gangrenosum in a pregnant patient., PMID:37905433
• Certolizumab pegol for hidradenitis suppurativa: Case report and literature review., PMID:33135826
• Certolizumab pegol for induction of remission in Crohn's disease., PMID:31476018
• ACG Clinical Guideline: Management of Crohn's Disease in Adults., PMID:29610508
• [Certolizumab]., PMID:31208736
• Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation., PMID:27140438
• Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis., PMID:31917928

Note

For research use only.

Images

Reférences

Fiche technique